We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recently, Novartis announced that it will invest in establishing a new radiopharmaceutical production site in China, in order to accelerate the introduction of innovative radioligand therapy to China.